The Collaborative Trajectory Analysis Project (cTAP), a public-private partnership to accelerate data science solutions to critical problems in drug development for Duchenne Muscular Dystrophy (Duchenne), today announced the publication of two research studies with important implications for the design of effective clinical trials.
Every Duchenne parent wants to know that their child is in good hands with their medical team. Physical therapy is an important part of that medical team, and Texas physical […]
NEWPORT BEACH, CA. October 25, 2016 – CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host an informational webinar on November 1, […]
Consortium Working Together to Bring Quality of Life Treatments to the Duchenne Community NEWPORT BEACH, Calif., October 25, 2016 – The next wave in tackling Duchenne Muscular Dystrophy is getting […]
A physical therapist is required to take on multiple roles while caring for their patients, and this is especially true when treating a complex condition such as Duchenne muscular […]
CureDuchenne hosted a webinar with Dr. Kevin Flanigan from Nationwide Children’s Hospital on October 12, 2016. The webinar was an opportunity for the Duchenne community to learn the most recent status of Dr. Flanigan’s duplication mutation research. Dr. Flanigan presented new data on his duplication 2 research.
Caring for a child with Duchenne can be daunting, complicated, and often times, isolating. But it doesn’t have to be. On October 22, CureDuchenne Cares will hold its inaugural Family […]
NEWPORT BEACH, Calif., October 7, 2016: CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host a webinar with Dr. Kevin Flanigan from […]
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage pharmaceutical company, today announced that target enrollment of 30 patients has been reached for Part B of the MoveDMD trial, a 12-week trial to assess the safety and efficacy of edasalonexent (CAT-1004) in Duchenne muscular dystrophy (DMD). Edasalonexent is an oral small molecule that the Company believes has the potential to be a disease-modifying therapy for DMD patients, regardless of their underlying dystrophin mutation.
